This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Stock Market News For July 17, 2018
by Zacks Equity Research
Financial stocks jumped on Monday although the broader market struggled, as impressive economic data and quarterly results failed to boost investors??? confidence.
Goldman Beats in Blankfein's Final Quarter
by Mark Vickery
Goldman Sachs (GS) CEO and Chairman Lloyd Blankfein announced his replacement this morning as the company he's run for the past 12 years easily beat earnings and revenue projections in its Q2 report.
J&J (JNJ) Ordered to Pay $4.69 Billion in Talc Lawsuit (Revised)
by Zacks Equity Research
A Missouri jury asked Johnson & Johnson (JNJ) to pay $4.69 billion in damages to 22 women and their families who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.
J&J (JNJ) Down on Trimmed View Despite Q2 Earnings Beat
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2018. However, it tightens its previously issued earnings guidance for 2018 while lowering its sales range.
Pacira Focused on Exparel Development Amid Competition
by Zacks Equity Research
Pacira (PCRX) focuses on the label expansion of its flagship product, Exparel.
Johnson & Johnson (JNJ) Slips 1.1% Ahead of Earnings: What To Watch
by Afrasiab Mian
Shares of Johnson & Johnson (JNJ) ticked down 1.1% during regular hours Monday, the last day of trading before it releases its latest quarterly earnings report. Investors displayed hesitation ahead of the report, but this is certainly still a stock to watch once the full results are in.
J&J's (JNJ) Invokana Label Expansion Filing Hit by FDA Delay
by Zacks Equity Research
The FDA defers decision regarding label expansion application to include cardiovascular indication on the label of J&J's (JNJ) diabetes drug Invokana.
Company News For Jul 16, 2018
by Zacks Equity Research
Companies in the news are: JNJ, T, AAPL and CSCO
The Zacks Analyst Blog Highlights: Johnson & Johnson, Novartis, UnitedHealth and Microsoft
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Novartis, UnitedHealth and Microsoft
Does the $4.7 Billion Talc Verdict Spell Trouble for J&J?
by David Borun
After a jury awards cancer victims a huge payout, is there more trouble ahead?
J&J (JNJ) to Pay $4.69 Billion to Some Women in Talc Lawsuit
by Zacks Equity Research
Johnson & Johnson (JNJ) has been ordered to pay $4.69 billion in damages to 22 families who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.
Will J&J's (JNJ) Pharma Segment Strength Drive Q2 Earnings?
by Zacks Equity Research
The positive trend seen in J&J's (JNJ) pharma segment sales in the past three quarters is likely to continue in Q2
Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit
by Zacks Equity Research
Pfizer (PFE) is re-organizing its business into three new units, effective 2019. A St Louis jury orders J&J (JNJ) to pay $4.69 billion in a lawsuit related to its talc-based products.
JNJ vs. NVS: Which Stock is Better Pre Q1 Earnings?
by Zacks Equity Research
With Johnson & Johnson (JNJ) and Novartis AG (NVS) scheduled to report on Jul 17 and Jul 18, respectively, this may be a good time to figure out which of these is a better stock.
AbbVie's Imbruvica Fails in Phase III Blood Cancer Study
by Zacks Equity Research
AbbVie's (ABBV) Imbruvica fails to meet the primary endpoint in a phase III study evaluating the drug in patients with DLBCL, a rare blood cancer, who have received no prior treatment.
Pfizer (PFE) to Reorganize Business Into Three New Units
by Zacks Equity Research
Pfizer (PFE) is re-organizing its business into three business segments, effective 2019. It is separating its consumer healthcare business into a standalone unit.
J&J (JNJ) to Set Pharma Q2 Earnings in Motion: What's Up?
by Zacks Equity Research
The positive trend seen in J&J's (JNJ) pharma segment sales in the past three quarters is likely to continue in Q2.
Pacira (PCRX) Issues Strong Preliminary Exparel Sales for Q2
by Zacks Equity Research
Pacira (PCRX) announces robust preliminary results for Exparel sales in second quarter on the back of increasing adoption for pain management in surgical procedures.
Pfizer to Defer Price Increases After Discussion With Trump
by Zacks Equity Research
Pfizer, Inc. (PFE) to defer its recent price increases of several prescription drugs after discussion with Trump.
Dow ETF in Focus Ahead of Q2 Earnings
by Sweta Killa
the Dow Jones closed above its 50-day moving average for the first time in nearly three weeks, a positive sign for its short-term momentum trend. As such, its proxy version DIA is in the spotlight heading into the earnings season.
Biogen's Alzheimer Disease Candidate Succeeds in Phase II
by Zacks Equity Research
Biogen's (BIIB) Alzheimer's disease (AD) candidate demonstrates statistically significant slowdown in disease progression and reduction of amyloid beta accumulation in the brain in a phase II study.
Pharma Stock Roundup: NVS to Divest Eye Care Unit, CHMP Gives Nod to Several Drugs
by Zacks Equity Research
Novartis (NVS) intends to spin off its Alcon eye care division. The CHMP gives positive opinion recommending marketing approval to several drugs.
3 Buy-Rated Large Cap Pharma Stocks to Boost Health in July
by Madhu Goel
We take a look at the three large cap pharma stocks that might be best bargains for the month of July.
Here's Why AbbVie Stock is Good for Your Portfolio's Health
by Zacks Equity Research
Here are six reasons why investing in AbbVie (ABBV) stock is a good decision now.
Is Pfizer's Price Hike an Effect of Drug Policy on Sector?
by Zacks Equity Research
Pfizer (PFE) reportedly raises prices of almost 100 drugs. The new drug policy has a soft stance with no provisions for direct negotiation by Medicare and resorts to competition for restricting price.